Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
- Cilloni, D.
- Renneville, A.
- Hermitte, F.
- Hills, R.K.
- Daly, S.
- Jovanovic, J.V.
- Gottardi, E.
- Fava, M.
- Schnittger, S.
- Weiss, T.
- Izzo, B.
- Nomdedeu, J.
- Heijden, A. van der
- Reijden, B.A. van der
- Jansen, J.H.
- Velden, V.H. van der
- Ommen, H.
- Preudhomme, C.
- Saglio, G.
- Grimwade, D.
DOIAbstract
Item does not contain fulltextPURPOSE: Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal residual disease (MRD). One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial. PATIENTS AND METHODS: Nine published and in-house real-time quantitative polymerase chain reaction WT1 assays were systematically evaluated within the European LeukemiaNet; the best-performing assay was applied to diagnostic ...
Add to ORKG